chromodomain helicase DNA binding protein 6Genealiases: CHD-6 · CHD5 · RIGB
Q-omics provides the consensus-scored CHD6 profile across patient tissues and cancer cell-line models. CHD6 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHD6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, CHD6 RNA expression shows 22,282 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CHD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHD6 survival associations across molecular data types. CHD6 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHD6 RNA expression–survival associations across cancer types. High CHD6 expression shows unfavorable associations in LIHC, but favorable associations in KIRC, SCLC, HNSC, UCS and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHD6 RNA expression.
This table summarizes CHD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CHD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHD6 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, CHOL, LIHC and STAD. The HNSC box plot shows higher CHD6 RNA expression in tumor versus normal tissue (log2 FC = +0.650, t-test p < 0.001).
This table shows molecular features associated with CHD6 in patient tissues and cancer cell lines. In patient samples, CHD6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
